Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GNT002
MIFTS: 56

Giant Cell Glioblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Giant Cell Glioblastoma

About this section

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 12 59 55 15 73
Monstrocellular Sarcoma 12 73

Characteristics:

Orphanet epidemiological data:

59
giant cell glioblastoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3074
MeSH 44 D005909
NCIt 50 C4325
SNOMED-CT 68 44529004
Orphanet 59 ORPHA251579
UMLS via Orphanet 74 C0334588
ICD10 via Orphanet 34 C71.9
Sources

Summaries for Giant Cell Glioblastoma

About this section
Disease Ontology : 12 A glioblastoma multiforme that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary : Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to glioblastoma and glioma susceptibility 1, and has symptoms including seizures and headache. An important gene associated with Giant Cell Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and PI3K/AKT activation. The drugs Procarbazine and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and prostate, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Sources

Related Diseases for Giant Cell Glioblastoma

About this section

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 glioblastoma 30.1 BRAF EGFR FGFR1 IDH1 MDM2 MGMT
2 glioma susceptibility 1 30.0 GFAP IDH1 PPARG TP53
3 papilloma of choroid plexus 29.9 GFAP SYP TP53
4 pleomorphic xanthoastrocytoma 29.9 BRAF GFAP IDH1 MGMT SYP TP53
5 ganglioglioma 29.8 BRAF GFAP SYP TP53
6 gemistocytic astrocytoma 29.8 GFAP PTEN
7 glioblastoma multiforme 29.3 EGFR GFAP IDH1 MDM2 MGMT PPARG
8 colorectal cancer 28.5 BRAF BUB1 EGFR FGFR3 MDM2 MGMT
9 gliosarcoma 28.2 EGFR FGFR1 FGFR3 GFAP IDH1 LZTR1
10 brain sarcoma 10.3
11 brain ependymoma 10.3 EGFR TP53
12 nevus of ota 10.3 BRAF TP53
13 plagiocephaly 10.2 FGFR1 FGFR3
14 adult oligodendroglioma 10.2 FGFR1 IDH1
15 oligoastrocytoma 10.2 GFAP MGMT
16 desmoplastic infantile ganglioglioma 10.2 GFAP SYP
17 papillary tumor of the pineal region 10.2 BRAF SYP
18 large cell carcinoma 10.2 EGFR FGFR1 SYP
19 pulmonary blastoma 10.2 EGFR SYP TP53
20 basaloid squamous cell carcinoma 10.2 EGFR SYP TP53
21 intracranial chondrosarcoma 10.2 IDH1 TP53
22 non-invasive bladder papillary urothelial neoplasm 10.2 FGFR3 TP53
23 lung benign neoplasm 10.2 EGFR SYP TP53
24 lung combined type small cell carcinoma 10.2 GFAP SYP
25 cerebellar astrocytoma 10.2 IDH1 TP53
26 frontal convexity meningioma 10.2 GFAP TP53
27 hyperplastic polyposis syndrome 10.2 BRAF TP53
28 gliofibroma 10.2 GFAP TP53
29 breast carcinoma in situ 10.2 EGFR FGFR1 TP53
30 colorectal adenocarcinoma 10.2 BRAF EGFR TP53
31 anaplastic oligodendroglioma 10.2 EGFR GFAP MGMT
32 osteoglophonic dysplasia 10.1 FGFR1 FGFR3
33 chiari malformation 10.1 FGFR3 GFAP SYP
34 cerebral convexity meningioma 10.1 GFAP TP53
35 cellular ependymoma 10.1 GFAP SYP TP53
36 central nervous system primitive neuroectodermal neoplasm 10.1 GFAP SYP TP53
37 lynch syndrome 10.1 BRAF EGFR MGMT TP53
38 cerebral neuroblastoma 10.1 GFAP SYP TP53
39 extraventricular neurocytoma 10.1 GFAP IDH1 SYP
40 cerebral ventricle cancer 10.1 GFAP SYP TP53
41 dysembryoplastic neuroepithelial tumor 10.1 GFAP IDH1 SYP
42 cystic teratoma 10.1 GFAP SYP TP53
43 teratoma 10.1 GFAP SYP TP53
44 central nervous system benign neoplasm 10.1 GFAP SYP TP53
45 angiocentric glioma 10.1 GFAP IDH1 SYP
46 cerebellar liponeurocytoma 10.1 GFAP SYP TP53
47 ring chromosome 7 10.1 MDM2 TP53
48 zika virus infection 10.1 MDM2 TP53
49 medullomyoblastoma 10.1 GFAP SYP TP53
50 protoplasmic astrocytoma 10.1 GFAP TP53

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma
Sources

Symptoms & Phenotypes for Giant Cell Glioblastoma

About this section

UMLS symptoms related to Giant Cell Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.28 EGFR
2 Decreased viability GR00173-A 10.28 AURKB
3 Decreased viability GR00221-A-1 10.28 AURKB EGFR FGFR1 FGFR3 PPARG
4 Decreased viability GR00221-A-2 10.28 AURKB FGFR1 FGFR3 PPARG
5 Decreased viability GR00221-A-3 10.28 FGFR3 PPARG
6 Decreased viability GR00221-A-4 10.28 AURKB EGFR PPARG
7 Decreased viability GR00402-S-2 10.28 AURKB EGFR FGFR1 FGFR3 PPARG
8 Decreased substrate adherent cell growth GR00193-A-1 9.97 BUB1
9 Decreased substrate adherent cell growth GR00193-A-2 9.97 AURKB BUB1
10 Decreased substrate adherent cell growth GR00193-A-3 9.97 BRAF BUB1
11 Decreased substrate adherent cell growth GR00193-A-4 9.97 AURKB BRAF BUB1 FGFR1
12 Decreased viability in esophageal squamous lineage GR00235-A 9.85 AURKB BRAF BUB3 FGFR3 GFAP IDH1
13 Condensed cis-Golgi GR00365-A 9.71 AURKB BUB1 FGFR1 PTEN
14 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.54 AURKB BRAF EGFR
15 Effect on mitosis GR00257-A-2 9.35 AURKB BUB1 BUB3 SYP TACC3
16 Increased cell death HMECs cells GR00103-A-0 9.1 BUB1 EGFR FGFR1 MDM2 PTEN TP53

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 AURKB BRAF BUB1 BUB3 EGFR FGFR1
2 growth/size/body region MP:0005378 10.46 AURKB BRAF BUB1 BUB3 EGFR FGFR1
3 homeostasis/metabolism MP:0005376 10.46 AURKB BRAF BUB1 BUB3 EGFR FGFR1
4 mortality/aging MP:0010768 10.42 AURKB BRAF BUB1 BUB3 EGFR FGFR1
5 hematopoietic system MP:0005397 10.38 BRAF BUB1 EGFR FGFR1 FGFR3 IDH1
6 immune system MP:0005387 10.36 BRAF BUB1 EGFR FGFR1 FGFR3 GFAP
7 endocrine/exocrine gland MP:0005379 10.33 BRAF BUB1 EGFR FGFR1 MDM2 MGMT
8 embryo MP:0005380 10.3 AURKB BRAF BUB3 EGFR FGFR1 MDM2
9 integument MP:0010771 10.28 AURKB BRAF BUB3 EGFR FGFR1 FGFR3
10 neoplasm MP:0002006 10.23 AURKB BRAF BUB1 BUB3 EGFR FGFR3
11 normal MP:0002873 10.22 BRAF BUB1 EGFR FGFR1 FGFR3 GFAP
12 digestive/alimentary MP:0005381 10.21 BRAF EGFR FGFR1 FGFR3 GFAP MDM2
13 craniofacial MP:0005382 10.16 BRAF EGFR FGFR1 FGFR3 MDM2 TACC3
14 limbs/digits/tail MP:0005371 10.13 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
15 muscle MP:0005369 10.13 BRAF BUB3 EGFR FGFR1 GFAP MDM2
16 liver/biliary system MP:0005370 10.11 BRAF BUB1 EGFR MDM2 PPARG PTEN
17 no phenotypic analysis MP:0003012 10.09 AURKB BUB1 EGFR FGFR1 FGFR3 MDM2
18 hearing/vestibular/ear MP:0005377 10.05 BRAF EGFR FGFR1 FGFR3 PPARG TP53
19 reproductive system MP:0005389 9.96 AURKB BRAF BUB1 EGFR FGFR1 FGFR3
20 renal/urinary system MP:0005367 9.92 BRAF EGFR FGFR1 FGFR3 MDM2 PPARG
21 pigmentation MP:0001186 9.77 BRAF EGFR MDM2 PTEN TP53
22 respiratory system MP:0005388 9.7 BRAF EGFR FGFR3 IDH1 MGMT PTEN
23 skeleton MP:0005390 9.7 BRAF BUB3 EGFR FGFR1 FGFR3 IDH1
24 vision/eye MP:0005391 9.28 BRAF BUB3 EGFR FGFR1 FGFR3 GFAP
Sources

Drugs & Therapeutics for Giant Cell Glioblastoma

About this section

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procarbazine Approved, Investigational Phase 3,Phase 1,Phase 2 671-16-9 4915
2
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
3
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Vincristine Approved, Investigational Phase 3,Phase 1 57-22-7, 2068-78-2 5978
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
11
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
12
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
13
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
14
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
17 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
20 Ether Phase 3
21 Photosensitizing Agents Phase 3,Phase 1,Phase 2
22 Dihematoporphyrin Ether Phase 3,Phase 1
23 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
25 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
27 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
28 O(6)-benzylguanine Phase 3,Phase 2,Phase 1,Not Applicable
29 Anesthetics, General Phase 3
30 Hematoporphyrin Derivative Phase 3
31 Hematoporphyrins Phase 3
32 Anesthetics, Inhalation Phase 3
33 Anesthetics Phase 3
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antimitotic Agents Phase 3,Phase 1,Phase 2
36 Cola Phase 3,Phase 1
37 Adjuvants, Anesthesia Phase 3
38 Liver Extracts Phase 3,Phase 2,Phase 1
39 Anesthetics, Intravenous Phase 3
40 Analgesics, Opioid Phase 3
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
42 Analgesics Phase 3,Phase 2,Phase 1
43 Narcotics Phase 3
44 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
45 Nootropic Agents Phase 3,Phase 2
46 Cholinergic Agents Phase 3,Phase 2
47 Cholinesterase Inhibitors Phase 3,Phase 2
48 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Central Nervous System Stimulants Phase 3,Phase 2
50 Dopamine Agents Phase 3,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 338)
# Name Status NCT ID Phase Drugs
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
4 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
5 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
6 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
7 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
8 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
9 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
10 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
11 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
17 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
18 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Unknown status NCT01013285 Phase 2 temozolomide
19 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
20 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2 hydroxychloroquine;temozolomide
21 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
22 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
23 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
24 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
25 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
26 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
27 Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00662506 Phase 1, Phase 2 Cediranib Maleate;Temozolomide
28 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
29 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00085254 Phase 1, Phase 2 cilengitide;temozolomide
30 Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM Completed NCT00004146 Phase 2 carboxyamidotriazole
31 Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00014170 Phase 2 gefitinib
32 Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00058097 Phase 2 tipifarnib
33 Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme Completed NCT00052208 Phase 1, Phase 2 gefitinib
34 Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors Completed NCT00039494 Phase 2 erlotinib hydrochloride;temozolomide
35 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed NCT01753713 Phase 2 dovitinib
36 GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Completed NCT00980343 Phase 2 vismodegib
37 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme Completed NCT00641706 Phase 2 vorinostat;bortezomib
38 Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
39 Pazopanib in Treating Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride
40 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma Completed NCT01310868 Phase 2 5-ALA;Gliadel wafers;Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist;Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
41 Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed NCT00445588 Phase 2 erlotinib hydrochloride;sorafenib tosylate
42 Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00423735 Phase 2 Dasatinib
43 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
44 AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT00305656 Phase 2 cediranib maleate
45 Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed NCT00238303 Phase 2 vorinostat
46 Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00974987 Phase 2 TMZ(temozolomide)
47 Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00643097 Phase 2 Temozolomide
48 CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
49 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Completed NCT00112502 Phase 2 Celecoxib;Isotretinoin;Temozolomide;Thalidomide
50 Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00099125 Phase 2 irinotecan hydrochloride;temozolomide

Search NIH Clinical Center for Giant Cell Glioblastoma

Sources

Genetic Tests for Giant Cell Glioblastoma

About this section
Sources

Anatomical Context for Giant Cell Glioblastoma

About this section

MalaCards organs/tissues related to Giant Cell Glioblastoma:

41
Brain, T Cells, Prostate, Bone, Spinal Cord, Lung, Liver
Sources

Publications for Giant Cell Glioblastoma

About this section

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 59)
# Title Authors Year
1
Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. ( 30368636 )
2018
2
Imaging findings in the progression of a giant cell glioblastoma. ( 30128062 )
2018
3
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. ( 30443141 )
2018
4
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. ( 29114311 )
2017
5
IDH-mutant giant cell glioblastoma: A neglected tumor variant? ( 29035191 )
2017
6
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. ( 27253461 )
2016
7
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. ( 26344331 )
2015
8
Giant cell glioblastoma with calcification and long-term survival. ( 26960525 )
2015
9
Genetic alterations in gliosarcoma and giant cell glioblastoma. ( 26443480 )
2015
10
Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients. ( 25037316 )
2014
11
Cerebellar giant cell glioblastoma multiforme in an adult. ( 25002780 )
2014
12
Giant cell glioblastoma in the pediatric age group: Report of two cases. ( 23772243 )
2013
13
Giant-cell glioblastoma of childhood associated with HIV-1 and JC virus coinfection. ( 23702739 )
2013
14
Recurrent giant cell glioblastoma with the neuroradiologic picture of multiple meningiomas. ( 22241593 )
2013
15
Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. ( 22943956 )
2013
16
Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma. ( 22286149 )
2012
17
Giant cell glioblastoma in a child: A rare case report. ( 23293671 )
2012
18
Cytomorphology of giant cell glioblastoma: Report of a case and brief review of literature. ( 21319330 )
2012
19
Acute tetraplegia and cardiac arrest following high cervical leptomeningeal metastasis of giant cell glioblastoma. ( 21658953 )
2011
20
Giant cell glioblastoma in the cerebrum of a Pembroke Welsh corgi. ( 21146179 )
2011
21
CD34 expression in glioblastoma and giant cell glioblastoma. ( 20175958 )
2010
22
A case of giant cell glioblastoma: a mimicker of a cerebral metastasis. ( 20973333 )
2010
23
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. ( 20467329 )
2010
24
Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. ( 19332771 )
2009
25
Exophytic giant cell glioblastoma of the medulla oblongata. ( 19061354 )
2009
26
Pediatric giant cell glioblastoma: New insights into a rare tumor entity. ( 19050301 )
2009
27
Long-Term Survival of a Patient with Giant Cell Glioblastoma: Case Report and Review of the Literature. ( 20740171 )
2009
28
Giant cell glioblastoma: review of the literature and illustrated case. ( 18726045 )
2008
29
Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations. ( 17498554 )
2007
30
Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. ( 17536538 )
2007
31
Giant cell glioblastoma multiforme: report of a case with prolonged survival and transformation to gliosarcoma. ( 16133270 )
2006
32
Pediatric giant cell glioblastoma: a case report and review of the literature. ( 15999285 )
2006
33
Lipidized giant-cell glioblastoma of cerebellum. ( 16320820 )
2005
34
Giant cell glioblastoma and pleomorphic xanthoastrocytoma. ( 15043454 )
2004
35
Heavily lipidized, calcified giant cell glioblastoma in an 8-year-old patient, associated with neurofibromatosis type 1 (NF1): report of a case with long-term survival. ( 15584213 )
2004
36
Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin. ( 12946225 )
2003
37
Giant cell glioblastoma manifesting as traumatic intracerebral hemorrhage--case report. ( 12513031 )
2002
38
Long-term survival of a patient with giant cell glioblastoma. Case report. ( 11302659 )
2001
39
Spinal leptomeningeal metastases of giant cell glioblastoma associated with subarachnoid haemorrhage: case report. ( 11148082 )
2001
40
Genetic profile of the giant cell glioblastoma. ( 10068201 )
1999
41
Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. ( 10320149 )
1999
42
Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. ( 9694343 )
1998
43
A clinico-immunohistochemical study of giant cell glioblastoma. ( 8916121 )
1996
44
Immunohistochemical analysis of giant cell glioblastoma. ( 7550996 )
1995
45
Giant cell glioblastoma in the frontal cortex of a dog. ( 7771064 )
1995
46
Multifocal giant cell glioblastoma: case report. ( 8362353 )
1993
47
Giant cell glioblastoma in a Syrian hamster. ( 1771744 )
1991
48
Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study. ( 2320202 )
1990
49
Giant cell glioblastoma: a work-up of 2 cases with long survival. ( 2718738 )
1989
50
A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line. ( 3840409 )
1985
Sources

Variations for Giant Cell Glioblastoma

About this section
Sources

Expression for Giant Cell Glioblastoma

About this section
Search GEO for disease gene expression data for Giant Cell Glioblastoma.
Sources

Pathways for Giant Cell Glioblastoma

About this section

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.84 AURKB BRAF EGFR FGFR1 FGFR3 GFAP
2
PI3K/AKT activation 66
Show member pathways
 13.1 EGFR FGFR1 FGFR3 MDM2 PTEN TP53
3
Phospholipase-C Pathway 64
Show member pathways
 13.01 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.98 EGFR FGFR1 FGFR3 MDM2 PTEN TP53
5
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.83 BRAF EGFR FGFR1 FGFR3 NFKBIA PTEN
6
Endometrial cancer 37
Show member pathways
 12.78 BRAF EGFR FGFR1 MDM2 NFKBIA PPARG
7
MAPK signaling pathway 37 1
12.74 BRAF EGFR FGFR1 FGFR3 TP53
8
Gastric cancer 37
Show member pathways
 12.74 BRAF EGFR FGFR1 PTEN TP53
9
Glioma 37
Show member pathways
 12.73 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
10
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.64 EGFR FGFR1 FGFR3 MDM2 NFKBIA PTEN
11
Pathways in cancer 37
12.53 BRAF EGFR FGFR1 FGFR3 MDM2 NFKBIA
12
Development EGFR signaling pathway 22
Show member pathways
 12.51 BRAF EGFR MDM2 NFKBIA TP53
13
DNA Damage 4
12.48 AURKB BUB3 MDM2 MGMT TACC3 TP53
14
MicroRNAs in cancer 37
12.47 EGFR FGFR3 MDM2 PTEN TP53
15
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.46 BRAF EGFR FGFR1 FGFR3 PTEN TP53
16
ErbB signaling pathway 1 37
Show member pathways
 12.45 BRAF EGFR MDM2 TP53
17
Apoptosis Pathway 72
Show member pathways
 12.39 EGFR FGFR1 FGFR3 MDM2 NFKBIA TP53
18
Development IGF-1 receptor signaling 22
Show member pathways
 12.37 MDM2 NFKBIA PTEN TP53
19
Cell cycle 1 37
12.34 BUB1 BUB3 MDM2 TP53
20
Proteoglycans in cancer 37
12.26 BRAF EGFR FGFR1 MDM2 TP53
21
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.23 BRAF NFKBIA PPARG TP53
22
VEGF Signaling Pathway 61 67
Show member pathways
 12.2 EGFR FGFR1 FGFR3 PTEN
23
Integrated Breast Cancer Pathway 1
12.13 BRAF EGFR MDM2 PTEN TP53
24
FoxO signaling pathway 37
Show member pathways
 12.06 BRAF EGFR MDM2 PTEN
25
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.05 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
26
AKT Signaling Pathway 67
12.04 EGFR FGFR1 FGFR3 MDM2 PTEN TP53
27
Direct p53 effectors 1
12.03 EGFR MDM2 PTEN TP53
28
Hepatitis C 37
12.02 BRAF EGFR NFKBIA TP53
29
MAPK Pathway 72
Show member pathways
 11.99 BRAF EGFR NFKBIA TP53
30
Senescence and Autophagy in Cancer 1
11.91 BRAF MDM2 PTEN TP53
31
Small cell lung cancer 37
11.84 NFKBIA PTEN TP53
32
Androgen receptor signaling pathway 1
11.83 EGFR MDM2 PTEN
33
ATM Pathway 64
Show member pathways
 11.81 MDM2 NFKBIA TP53
34
Glioblastoma Multiforme 64
11.78 BRAF EGFR MDM2 MGMT PTEN TP53
35
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.77 FGFR1 FGFR3 GFAP SYP
36
Bladder cancer 37 1
11.63 BRAF EGFR FGFR3 MDM2 TP53
37
Cell cycle_Role of APC in cell cycle regulation 22
11.57 AURKB BUB1 BUB3
38
Copper homeostasis 1
11.57 MDM2 PTEN TP53
39
Proteolysis Putative SUMO-1 pathway 22
Show member pathways
 11.56 MDM2 NFKBIA TP53
40
Integrated Cancer Pathway 1
11.49 MDM2 PTEN TP53
41
Alzheimers Disease Pathway 64
11.47 EGFR FGFR1 FGFR3
42
Aurora B signaling 1
Show member pathways
 11.47 AURKB BUB1 TACC1
43
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.45 MDM2 NFKBIA TP53
44
Vemurafenib Pathway, Pharmacodynamics 61
11.4 BRAF EGFR FGFR1 FGFR3
45
G-protein signaling_Cross-talk between Ras-family GTPases 22
11.37 BRAF EGFR FGFR1 FGFR3
46
Central carbon metabolism in cancer 37
11.25 EGFR FGFR1 FGFR3 IDH1 PTEN TP53
47
Aurora A signaling 1
10.59 AURKB MDM2 NFKBIA TACC1 TACC3 TP53
Sources

GO Terms for Giant Cell Glioblastoma

About this section

Cellular components related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 AURKB BRAF BUB1 BUB3 FGFR1 GFAP
2 cytoplasm GO:0005737 9.5 AURKB BRAF EGFR FGFR1 FGFR3 GFAP
3 nucleus GO:0005634 10 AURKB BRAF BUB1 BUB3 EGFR FGFR1

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.97 AURKB BRAF BUB1 EGFR FGFR1 FGFR3
2 protein deubiquitination GO:0016579 9.93 MDM2 NFKBIA PTEN TP53
3 MAPK cascade GO:0000165 9.9 BRAF EGFR FGFR1 FGFR3
4 cell cycle GO:0007049 9.87 AURKB BUB1 BUB3 SEPT14 TACC1 TACC3
5 cell division GO:0051301 9.85 AURKB BUB1 BUB3 SEPT14 TACC1 TACC3
6 peptidyl-tyrosine phosphorylation GO:0018108 9.84 BRAF EGFR FGFR1 FGFR3
7 regulation of cell proliferation GO:0042127 9.83 BRAF EGFR FGFR1 NFKBIA
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 BRAF EGFR FGFR1 FGFR3 PTEN
9 protein autophosphorylation GO:0046777 9.81 AURKB EGFR FGFR1 FGFR3
10 regulation of signal transduction by p53 class mediator GO:1901796 9.79 AURKB MDM2 TP53
11 cellular response to drug GO:0035690 9.75 BRAF EGFR TP53
12 long-term synaptic potentiation GO:0060291 9.65 BRAF GFAP PTEN
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.63 NFKBIA PPARG
14 negative regulation of telomerase activity GO:0051974 9.62 PPARG TP53
15 protein localization to kinetochore GO:0034501 9.62 AURKB BUB3
16 salivary gland morphogenesis GO:0007435 9.61 EGFR FGFR1
17 attachment of spindle microtubules to kinetochore GO:0008608 9.59 AURKB BUB3
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.58 EGFR TP53
19 mitotic spindle assembly checkpoint GO:0007094 9.58 AURKB BUB1 BUB3
20 positive regulation of phospholipase activity GO:0010518 9.57 FGFR1 FGFR3
21 regulation of axon regeneration GO:0048679 9.56 BRAF PTEN
22 response to organic cyclic compound GO:0014070 9.55 EGFR IDH1 MGMT PPARG PTEN
23 cell proliferation GO:0008283 9.5 AURKB BUB1 EGFR PTEN TACC1 TACC3
24 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
25 regulation of chromosome segregation GO:0051983 9.43 AURKB BUB1 BUB3
26 negative regulation of apoptotic process GO:0043066 9.28 BRAF EGFR FGFR1 FGFR3 MDM2 MGMT
27 positive regulation of cell proliferation GO:0008284 10.04 EGFR FGFR1 FGFR3 MDM2 PTEN
28 phosphorylation GO:0016310 10.02 AURKB BRAF BUB1 EGFR FGFR1 FGFR3

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.85 AURKB BRAF EGFR FGFR1 FGFR3
2 kinase activity GO:0016301 9.85 AURKB BRAF BUB1 EGFR FGFR1 FGFR3
3 protein phosphatase binding GO:0019903 9.69 EGFR PPARG TP53
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.65 EGFR FGFR1 FGFR3
5 protein kinase activity GO:0004672 9.63 AURKB BRAF BUB1 EGFR FGFR1 FGFR3
6 protein tyrosine kinase activity GO:0004713 9.62 BRAF EGFR FGFR1 FGFR3
7 protein self-association GO:0043621 9.61 PPARG SYP TP53
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR1 FGFR3
9 enzyme binding GO:0019899 9.43 EGFR MDM2 NFKBIA PPARG PTEN TP53
10 identical protein binding GO:0042802 9.4 BRAF EGFR FGFR1 FGFR3 GFAP IDH1
11 fibroblast growth factor-activated receptor activity GO:0005007 9.26 FGFR1 FGFR3
12 transferase activity GO:0016740 10.1 AURKB BRAF BUB1 EGFR FGFR1 FGFR3
Sources

Sources for Giant Cell Glioblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....